Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Avadel Pharmaceuticals
AVDL
Avadel Pharmaceuticals
Reliance On Single Therapy Will Trigger Competition Yet Secure Recovery
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
28 Aug 25
Updated
28 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$16.00
8.6% undervalued
intrinsic discount
28 Aug
US$14.62
1Y
-1.8%
7D
-1.3%
Loading
1Y
-1.8%
7D
-1.3%
Author's Valuation
US$16.0
8.6% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$16.0
8.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-159m
415m
2014
2017
2020
2023
2025
2026
2028
Revenue US$414.5m
Earnings US$84.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
17.42%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
7.16%
Calculation
US$83.97m
Earnings '28
x
23.21x
PE Ratio '28
=
US$1.95b
Market Cap '28
US$1.95b
Market Cap '28
/
99.34m
No. shares '28
=
US$19.62
Share Price '28
US$19.62
Share Price '28
Discounted to 2025 @ 7.16% p.a.
=
US$15.95
Fair Value '25
